The risk of heart attack and stroke is a concern for older people and knowing there is an effective measure for lowering that risk will be a huge reassurance to older people and their families. We hope to see updated guidelines to help clinicians make use of these new findings.

Viktor Kočka

In contrast to interventions for myocardial infarction or stroke, there have been very few advances in the treatment of [PE] over the last 20 years. This has led to a considerable unmet clinical need that we can't ignore.

Jörg Hausleiter

Among these high-risk patients, transcatheter tricuspid valve repair on top of medical therapy resulted not only in quality-of-life improvements but also in meaningful and sustained reductions in hard clinical outcomes, which has not been demonstrated before with the intervention.

Importantly, this was not because coronary access was impaired after TAVI. Rather, once the valve had been treated, the clinical decision about whether PCI was still necessary sometimes changed.

“Despite major advances in pharmacologic and device-based therapies, pulmonary hypertension remains one of the strongest predictors of hospitalization, right ventricular failure, and death in patients with left heart disease and heart failure.”

Early ECG monitoring did not lead to lower recurrence of syncope than standard care. This finding probably reflects the multifactorial nature of syncope, with a clinically important arrhythmia identified in only 22.0% of the intervention group, a result that limited the effects of rhythm-directed...

For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease.

“Why is this important in terms of safety? Because milvexian is currently being evaluated in two other large trials: one in atrial fibrillation and one in secondary stroke prevention.”

BHF Professor of Cardiology, University of Edinburgh, University of Edinburgh

Our findings provide strong evidence that patients who have had a heart attack excluded do not benefit from early outpatient CTCA scans. Once we are confident that they haven't had a heart attack, we can reassure these patients that their future risk is low and send them home.

Extended DAPT provided greater protection against major ischemic events, including death, whereas clopidogrel monotherapy reduced major or clinically relevant bleeding. It seems that no single strategy is best for every patient, but rather, long-term antiplatelet therapy should be individualized ...